These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 16033823)
1. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Tommiska J; Eerola H; Heinonen M; Salonen L; Kaare M; Tallila J; Ristimäki A; von Smitten K; Aittomäki K; Heikkilä P; Blomqvist C; Nevanlinna H Clin Cancer Res; 2005 Jul; 11(14):5098-103. PubMed ID: 16033823 [TBL] [Abstract][Full Text] [Related]
2. Association of BRCA2 polymorphism at codon 784 (Met/Val) with breast cancer risk and prognosis. Ishitobi M; Miyoshi Y; Ando A; Hasegawa S; Egawa C; Tamaki Y; Monden M; Noguchi S Clin Cancer Res; 2003 Apr; 9(4):1376-80. PubMed ID: 12684407 [TBL] [Abstract][Full Text] [Related]
3. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival. Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124 [TBL] [Abstract][Full Text] [Related]
4. Genetic variation in pro-inflammatory cytokines (interleukin-1beta, interleukin-1alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma. Snoussi K; Strosberg AD; Bouaouina N; Ben Ahmed S; Chouchane L Eur Cytokine Netw; 2005 Dec; 16(4):253-60. PubMed ID: 16464738 [TBL] [Abstract][Full Text] [Related]
5. P27 V109G Polymorphism is associated with lymph node metastases but not with increased risk of breast cancer. Naidu R; Har YC; Taib NA J Exp Clin Cancer Res; 2007 Mar; 26(1):133-40. PubMed ID: 17550142 [TBL] [Abstract][Full Text] [Related]
6. P53 codon 72 polymorphism in breast cancer. Buyru N; Tigli H; Dalay N Oncol Rep; 2003; 10(3):711-4. PubMed ID: 12684648 [TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Kröger N; Milde-Langosch K; Riethdorf S; Schmoor C; Schumacher M; Zander AR; Löning T Clin Cancer Res; 2006 Jan; 12(1):159-68. PubMed ID: 16397038 [TBL] [Abstract][Full Text] [Related]
8. Elevated preoperative serum ICTP is a prognostic factor for overall and disease-free survival in breast cancer. Keskikuru R; Bloigu R; Risteli J; Kataja V; Jukkola A Oncol Rep; 2002; 9(6):1323-7. PubMed ID: 12375042 [TBL] [Abstract][Full Text] [Related]
9. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579 [TBL] [Abstract][Full Text] [Related]
10. p53 mutation in plasma DNA and its prognostic value in breast cancer patients. Shao ZM; Wu J; Shen ZZ; Nguyen M Clin Cancer Res; 2001 Aug; 7(8):2222-7. PubMed ID: 11489795 [TBL] [Abstract][Full Text] [Related]
11. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Xu Y; Yao L; Ouyang T; Li J; Wang T; Fan Z; Lin B; Lu Y; Xie Y Clin Cancer Res; 2005 Oct; 11(20):7328-33. PubMed ID: 16243804 [TBL] [Abstract][Full Text] [Related]
12. Her2 genotype and breast cancer progression in Korean women. An HJ; Kim NK; Oh D; Kim SH; Park MJ; Jung MY; Kang H; Kim SG; Lee KP; Lee KS Pathol Int; 2005 Feb; 55(2):48-52. PubMed ID: 15693849 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism. Papadopoulou E; Anagnostopoulos K; Tripsianis G; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A Neoplasma; 2008; 55(3):229-38. PubMed ID: 18348656 [TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Jin Q; Hemminki K; Enquist K; Lenner P; Grzybowska E; Klaes R; Henriksson R; Chen B; Pamula J; Pekala W; Zientek H; Rogozinska-Szczepka J; Utracka-Hutka B; Hallmans G; Försti A Clin Cancer Res; 2005 May; 11(10):3647-53. PubMed ID: 15897560 [TBL] [Abstract][Full Text] [Related]
15. Association of cyclin D1 genotype with breast cancer risk and survival. Shu XO; Moore DB; Cai Q; Cheng J; Wen W; Pierce L; Cai H; Gao YT; Zheng W Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):91-7. PubMed ID: 15668481 [TBL] [Abstract][Full Text] [Related]
16. Association of p53 polymorphisms with breast cancer: a case-control study in Slovak population. Franeková M; Zúbor P; Stanclová A; Dussan CA; Bohusová T; Galo S; Dobrota D; Kajo K; Péc M; Racay P Neoplasma; 2007; 54(2):155-61. PubMed ID: 17319790 [TBL] [Abstract][Full Text] [Related]
17. Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Noma C; Miyoshi Y; Taguchi T; Tamaki Y; Noguchi S Cancer Lett; 2004 Jul; 210(2):197-203. PubMed ID: 15183535 [TBL] [Abstract][Full Text] [Related]
18. Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma? Sullivan PS; Apple SK Breast J; 2009; 15(2):146-54. PubMed ID: 19292800 [TBL] [Abstract][Full Text] [Related]
19. A polymorphism C3435T of the MDR-1 gene associated with smoking or high body mass index increases the risk of sporadic breast cancer in women. Zubor P; Lasabova Z; Hatok J; Stanclova A; Danko J Oncol Rep; 2007 Jul; 18(1):211-7. PubMed ID: 17549370 [TBL] [Abstract][Full Text] [Related]
20. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients. Kwiatkowska E; Teresiak M; Filas V; Karczewska A; Breborowicz D; Mackiewicz A Clin Cancer Res; 2003 Oct; 9(12):4452-9. PubMed ID: 14555518 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]